S&P 500 Financials Sector SEC Filings — March 10, 2026

10-03-2026

Trio Petroleum Corp filed its fourth amendment to the Prospectus Supplement for its At Market Issuance Sales Agreement (ATM Agreement) dated January 9, 2026, reporting $17.4M in Common Stock sales (18.1M shares) across prior amendments, leaving $1.6M available out of a $19.0M maximum aggregate offering. This rapid fundraising since January provides needed capital but implies significant shareholder dilution from the large share issuance. A legal opinion for the remaining Placement Shares was attached.

• ·ATM Agreement and initial Prospectus Supplement filed January 9, 2026, under Registration Statement effective September 10, 2024.
• ·Amendment No. 1 filed March 3, 2026; Amendment No. 2 on March 4, 2026; Amendment No. 3 on March 5, 2026.
• ·Common Stock par value $0.0001 per share, traded as TPET on NYSE American.

10-03-2026

Elevance Health, Inc. reaffirmed its FY2026 adjusted shareholders’ earnings guidance at least $25.50 per diluted share and benefit expense ratio of 90.2% plus or minus 50 basis points, incorporating the potential impact of CMS sanctions. These sanctions, notified on February 27, 2026, would suspend Medicare Advantage-Prescription Drug plan enrollments and certain communications effective March 31, 2026, unless resolved. The guidance reflects confidence despite this regulatory risk.

• ·CMS notified Company of sanctions intent on February 27, 2026, as reported in prior 8-K filed March 2, 2026
• ·Sanctions effective March 31, 2026, unless issues addressed
• ·No GAAP reconciliation provided for adjusted EPS guidance due to uncertain financial payments related to sanctions

10-03-2026

Craig Abrahams notified Playtika Holding Corp. of his resignation as President and Chief Financial Officer, effective April 1, 2026, with no relation to financial issues or disagreements. The board appointed Tae Lee as acting Chief Financial Officer and principal financial officer effective the same date, and updated Robert Antokol's title to Chief Executive Officer, President, and Chairperson of the Board. No changes to Antokol's compensation and no material interests or family relationships for the involved parties.

• ·Tae Lee, age 41, previously Corporate Finance Manager at Meta Platforms, Inc. from 2019-2021; MBA from Columbia Business School; BA in Economics from University of Chicago.
• ·Mr. Lee's compensation as acting CFO not yet determined; to be filed as amendment.
• ·Reference to 2025 Proxy Statement filed April 25, 2025, for Antokol's compensation and experience.
• ·No arrangements, understandings, or family relationships for Lee or Antokol; no material interests exceeding $120,000 threshold.

10-03-2026

Seaport Entertainment Group Inc., a Delaware corporation and emerging growth company listed on NYSE (SEG), filed a Form S-3 shelf registration statement on March 9, 2026, to offer up to $150M in common stock, preferred stock, warrants, rights, and units from time to time on a delayed or continuous basis. Common stock closed at $21.64 per share on March 6, 2026. No specific terms or immediate sales are detailed; future prospectus supplements will provide offering specifics.

• ·Registrant is an accelerated filer and emerging growth company (elected not to use extended transition period for accounting standards).
• ·Principal executive offices: 199 Water Street, 28th Floor, New York, NY 10038.
• ·Incorporates by reference: 10-K for FY ended December 31, 2025 (filed March 4, 2026); 8-Ks on January 29, 2026 and February 9, 2026; Definitive Proxy on April 23, 2025; Form 10 effective July 24, 2024.

10-03-2026

Climate Transition Special Opportunities SPAC I, a Cayman Islands blank check company targeting mergers in climate transition, specialty finance, renewable energy, and regenerative agriculture sectors, filed Amendment No. 3 to its S-1 registration statement for a $150M IPO of 15M units at $10 each, consisting of one Class A ordinary share and one-third of a redeemable warrant exercisable at $11.50. Net proceeds before expenses are $141M, with $150M (or $172.5M if over-allotment exercised) to be placed in trust; sponsor holds 5,675,000 founder shares after share split and transfers. No target identified yet, and investing involves high risks as noted in the prospectus.

• ·Warrants exercisable 30 days after initial business combination, expire 5 years post-combination
• ·Underwriting over-allotment option: 45 days from prospectus date
• ·Separate trading of shares and warrants expected on 52nd day post-prospectus
• ·NYSE listing intended: CLSO U (units), CLSO (shares), CLSO WS (warrants)
• ·Sponsor transferred 25,000 founder shares to each independent director (total 75,000) at ~$0.004/share

10-03-2026

Aclaris Therapeutics, Inc. sold 12.7 million shares of its common stock for aggregate gross proceeds of $39.8 million from March 2, 2026, through March 9, 2026, pursuant to its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. The shares were purchased by institutional investors, including Deep Track Capital. No other financial metrics or period-over-period comparisons were disclosed.

• ·Sales occurred from March 2, 2026, through March 9, 2026
• ·Information under Item 7.01 is not deemed 'filed' for liability purposes per General Instruction B.2.

10-03-2026

UWM Holdings Corporation filed a Form 8-K on March 10, 2026, reporting a press release issued on March 9, 2026, under Item 7.01 Regulation FD Disclosure, with the press release furnished as Exhibit 99.1. The filing was signed by Rami Hasani, Executive Vice President and Chief Financial Officer. No specific financial or operational details from the press release are included in the filing body.

• ·Securities registered: Class A Common Stock (UWMC) on New York Stock Exchange
• ·Company address: 585 South Boulevard E., Pontiac, Michigan 48341
• ·Registrant’s telephone: (800) 981-8898

10-03-2026

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced a $40M private placement financing, expecting gross proceeds from selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant. The financing includes participation from Coastlands Capital, Commodore Capital, Vivo Capital, and other institutional investors, with Leerink Partners as exclusive placement agent. The transaction is expected to close on March 10, 2026, subject to customary conditions.

• ·Pre-funded warrants exercisable immediately at $0.00001 per share until fully exercised, subject to ownership limits.
• ·Private placement conducted per Nasdaq rules, priced at Minimum Price requirement.
• ·AN2 Therapeutics to file SEC registration statement for resale of shares and warrant shares.
• ·Pipeline targets: polycythemia vera, NTM lung disease (M. abscessus), Chagas disease, melioidosis, oncology, infectious diseases.

10-03-2026

Belpointe PREP, LLC, through its indirect subsidiary BPOZ 100 Tokeneke Holding, LLC, entered into a $5M convertible promissory note at 3.6% interest, due March 3, 2028, with 100 Tokeneke Road, LLC to fund the purchase of real property at 100 Tokeneke Road, Darien, Connecticut. Concurrently, Belpointe Tokeneke Investment, LLC—a related party indirectly owned by family members of CEO Brandon E. Lacoff—provided a $3.25M loan on similar terms, including a mandatory $0.625M conversion granting it 50% ownership in 100 Tokeneke Partners, LLC. The transactions were approved by the Company's Conflicts Committee in compliance with related party policies.

• ·Loan origination date: March 3, 2026
• ·Loan maturity date: March 3, 2028
• ·Property address: 100 Tokeneke Road, Darien, Connecticut
• ·Filing is Amendment No. 1 to correct scrivener’s error on maturity dates in initial 8-K filed March 9, 2026

10-03-2026

Lipocine Inc. (LPCN) filed its 10-K annual report on March 10, 2026, outlining extensive risk factors including the need for substantial additional capital to fund clinical trials and operations, potential delays in regulatory approvals, and challenges in commercializing TLANDO and product candidates such as LPCN 1154, LPCN 2201, LPCN 2101, LPCN 2203, LPCN 2401, and LPCN 1148. The filing emphasizes uncertainties in achieving profitability, stock price volatility, competition in the TRT market, and risks of delisting from Nasdaq Capital Market. No financial performance data or period-over-period comparisons were detailed in the provided risk factor excerpts.

• ·Risks include FDA Advisory Committee meetings, Phase 4 study commitments, and REMS requirements
• ·Potential for product recalls, withdrawals, or litigation impacting revenues
• ·Anti-takeover provisions in amended certificate of incorporation, bylaws, and stockholder rights plan

10-03-2026

Total assets grew 38% to $1.53M as of January 31, 2026, driven by $446M net proceeds from share issuances that boosted cash and cash equivalents to $0.49M from $0.15M, while total equity rose 44% to $1.41M. However, quarterly sales declined 59% YoY to $20.2k with gross profit down 45% to $10k, amid sharply higher mineral property expenditures up 66% to $23.7k and total operating costs up 54% to $33.6k, leading to an operational loss widening to $23.6k from $3.6k. For the six months, net loss improved 20% to $24.3k from $30.4k, but cash used in operations surged to $72.4k from $20.3k.

• ·Investment in equity securities increased to $84k from $28k.
• ·Equity-accounted investments rose to $60k from $56k.
• ·Current liabilities decreased to $21k from $26k.
• ·Mineral rights and properties slightly up to $713k from $710k.
• ·Net cash used in investing activities $37k vs $136k prior six months.

10-03-2026

News Corporation disclosed updates to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program, which authorizes the acquisition of up to $1 billion in aggregate of Class A (NWSA) and Class B (NWS) common stock. The 8-K filing attaches Exhibits 99.1 and 99.2 containing the specific information provided to the ASX on the respective dates. No specific repurchase transactions or amounts were detailed in the filing body.

• ·Filing reports event date of March 9, 2026
• ·Securities: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01)

10-03-2026

Trailblazer Merger Corp I reported a net loss of $8.3M for the year ended December 31, 2025, compared to net income of $0.28M in 2024, primarily due to a $6.2M loss on debt extinguishment and $0.2M loss on fair value changes, despite $0.94M in interest income. Total assets declined 84% YoY to $4.3M from $27.7M, driven by Trust Account reduction to $4.0M from $26.8M amid heavy redemptions of Class A shares (down to 333K shares from 2.4M). Liabilities rose to $16.2M from $7.2M with $11.0M in new convertible promissory notes, worsening stockholders' deficit to $15.9M from $6.1M, while operating costs increased 12% YoY.

• ·Class A redeemable shares at $11.76/share in 2025 (vs $11.19/share in 2024)
• ·Excise tax payable increased to $912,593 from $497,749
• ·Promissory note - related party extinguished; new convertible note $11.0M with related party
• ·Net cash used in operating activities worsened to $2.55M from $1.56M
• ·Cash paid for income taxes $1.04M in 2025 vs $0.35M in 2024

10-03-2026

Arq, Inc. reported revenue growth of 10% YoY to $120.3M in 2025 from $109.0M in 2024, with Adjusted EBITDA improving to $13.2M from $10.5M and SG&A expenses declining 21%. However, net loss widened dramatically to $52.6M from $5.1M, driven by a $44.8M impairment of long-lived assets and a 25% increase in cost of revenue; operating cash flow turned negative at $2.7M versus positive $10.5M prior year. Total assets decreased to $230.6M from $284.4M, reflecting impairments and asset write-downs.

• ·Property, plant and equipment net: $143.2M (2025) vs $178.6M (2024)
• ·Revolving credit facility increased to $19.0M (2025) from $13.8M (2024)
• ·Weighted-average basic shares outstanding: 41,522 (thousands) in 2025 vs 36,051 (thousands) in 2024
• ·Basic loss per share: $(1.27) (2025) vs $(0.14) (2024)

10-03-2026

Alexander & Baldwin, Inc. held a special shareholder meeting on March 9, 2026, approving all three proposals related to the Merger Agreement dated December 8, 2025, with Tropic Purchaser LLC and Tropic Merger Sub LLC. The Merger Agreement Proposal passed overwhelmingly with 57,355,918 votes for, 424,197 against, and 113,557 abstentions on a quorum of 57,893,672 shares (79.50% of 72,820,075 outstanding shares). The merger is expected to close on or about March 12, 2026, subject to conditions.

• ·Record date for Special Meeting: January 15, 2026.
• ·Definitive Proxy Statement first mailed to shareholders on or about January 23, 2026.
• ·No broker non-votes occurred as proposals were non-routine.
• ·No other business came before the Special Meeting.

10-03-2026

Galaxy Enterprises Inc., a shell company, reported a narrowed net loss of $9,748 for the fiscal year ended July 31, 2025, compared to $20,135 in FY 2024, driven by a 52% reduction in general and administrative expenses. However, cash balance declined 71% to $185 from $638, total liabilities rose 24% to $48,447 from $39,152, and the stockholders' equity deficiency worsened to $(33,262) from $(23,514). Total assets edged down 3% to $15,185 from $15,638 amid ongoing cash burn from operations.

• ·Entity classified as shell company, small business, and emerging growth company.
• ·Auditor: LAO Professionals (Firm ID 7057, Lagos, Nigeria).
• ·No revenue reported; only operating expenses.
• ·Prepayments and deposits unchanged at $15,000.

10-03-2026

York Space Systems Inc. (YSS) entered into a Merger Agreement on March 6, 2026, to acquire all issued and outstanding equity interests of Orbion Space Technology, Inc. in exchange for cash and 2,812,141 shares of YSS common stock. The shares, subject to transfer restrictions, were issued under a Section 4(a)(2) exemption from Securities Act registration requirements.

• ·Merger involves Orbion sellers’ representative.
• ·Filing signed March 9, 2026; reported under Item 3.02 Unregistered Sales of Equity Securities.

10-03-2026

Creative Media & Community Trust Corp (CMCT) reported total revenues of $116.7M for the year ended December 31, 2025, down 6.3% YoY from $124.5M, with declines in office (-7.6%), multifamily (-19.1%), and lending (-16.7%) segments offsetting hotel growth of 4.9%. Net loss widened 53.7% to $39.6M from $25.8M amid higher expenses (+2.7%) and a $3.7M real estate impairment, though FFO attributable to common stockholders improved to -$31.5M from -$46.3M and total assets stood at $859.2M, down from $889.6M.

• ·Sheraton Grand Hotel (Sacramento, CA) had 72.5% occupancy and $152.70 RevPAR.
• ·Investments in real estate, net: $698.1M (2025) vs. $709.2M (2024).
• ·Loans receivable, net: $0 (2025) vs. $56.2M (2024).
• ·Net loss attributable to common stockholders per share: $(67.08) basic and diluted (2025) vs. $(431.43) (2024).
• ·Weighted average common shares outstanding: 919K basic and diluted (2025) vs. 170K (2024).

10-03-2026

Guided Therapeutics, Inc. completed a Warrant Exchange on March 2, 2026, for eligible warrants from its September 1, 2022 Private Offering, with 4,825,000 warrant shares (22.7% of outstanding eligible warrants) tendered, resulting in $980,000 cash proceeds and issuance of 4,825,000 restricted common shares. Shares outstanding increased from 86,691,976 to 91,516,976, representing about 5.6% dilution. However, participation was low, leaving 16,398,080 eligible warrants outstanding, with expirations in 2026 and 2027.

• ·Eligible warrants originally priced at $0.65 exchanged at $0.25; those at $0.50 at $0.20.
• ·Expiration of Warrant Exchange: February 25, 2026 at 8:00 a.m. ET.
• ·Offer to Exchange dated February 11, 2026.
• ·Of remaining warrants: 11,973,080 expire Sep 1-Oct 18, 2026; 4,425,000 expire Sep 1-Oct 18, 2027.
• ·Shares issued in reliance on Section 3(a)(9) exemption; no commissions paid.

10-03-2026

dMY Squared Technology Group, Inc., Horizon Quantum Holdings Ltd., and Horizon Quantum Computing Pte. Ltd. amended PIPE Subscription Agreements with certain investors, introducing a 'Reduction Right' allowing them to satisfy part of their $111.9M PIPE commitment using dMY Class A common shares owned or purchased in the open market, subject to specific voting and non-redemption conditions, ahead of the Business Combination special meeting. The amendment to the IonQ side letter removes the prior condition requiring a commercial agreement for quantum hardware purchase, facilitating IonQ's participation. No financial declines or flat metrics are reported, but the filing highlights ongoing risks to deal completion.

• ·PIPE Subscription Agreements originally dated December 4, 2025 and March 6, 2026
• ·Amendment to PIPE Agreements and IonQ Side Letter executed March 9, 2026
• ·Reduction Right election deadline: one Business Day prior to dMY stockholder redemption deadline
• ·Business Combination Agreement dated September 9, 2025
• ·Registration Statement effective February 17, 2026; definitive Proxy Statement mailed same day

10-03-2026

Sturm, Ruger & Company, Inc. (RGR) filed Amendment No. 1 to its Form 8-K on March 10, 2026, to include a corrected press release issued on March 9, 2026, responding to public statements by Beretta Holding S.A. regarding its nomination of director candidates for RGR's 2026 annual meeting of stockholders. The filing is soliciting material under Rule 14a-12. No financial metrics or performance data are provided.

10-03-2026

ACRES Commercial Realty Corp's total investment portfolio reached $1.96B at December 31, 2025, with CRE whole loans comprising 91.74% ($1.80B net carrying amount). Net interest income declined 19% YoY to $33.2M from $41.2M, driven by a 24% drop in interest income primarily from 25% lower CRE whole loan volumes and yield compression from 9.01% to 7.62%, though offset somewhat by a 26% decrease in interest expense. Positively, real estate income grew 11% to $46.6M and total operating expenses fell 12% to $63.5M, boosted by a $7.7M reversal of credit loss provisions.

• ·Tax loss carryforwards as of 2024 return: REIT QRS operating $32.1M (unlimited life), capital $115.9M (5 years); TRS operating $62.0M (various), capital $20.8M (5 years).
• ·Properties held for sale: $67.5M (3.44% of portfolio) at Dec 31, 2025.
• ·Average yield on CRE whole loans declined from 9.22% in 2024 to 7.67% in 2025.
• ·Management fees - related party down 1% YoY to $6.4M.

10-03-2026

For the nine months ended January 31, 2026, GPO Plus, Inc. reported revenues of $4.1M, up 12% YoY from $3.6M, with gross profit rising 28% to $1.1M driven by improved margins. However, operating expenses surged 21% to $2.6M, resulting in a widened operating loss of $1.5M and net loss of $2.0M versus $1.6M prior year, while Q3 revenues fell 2% YoY to $1.2M and net loss more than doubled to $748K. Cash balances plummeted 95% to $18K from $336K at fiscal year-end, with total assets down 18% to $0.65M amid rising liabilities.

• ·Net cash used in operating activities for nine months: $1.0M (worsened from $0.8M YoY)
• ·Promissory note payable net: $3.4M as of Jan 31, 2026 (up from $2.6M)
• ·Stockholders' deficit worsened to $8.2M from $7.3M
• ·Finance lease right-of-use assets increased to $408K from $206K

10-03-2026

Centene Corporation announced its presentation at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where it will reaffirm 2026 full year GAAP diluted EPS guidance of greater than $1.98 and adjusted diluted EPS guidance of greater than $3.00. Separately, the company issued a notice for partial redemption of $1B aggregate principal amount of its 4.25% Notes due December 15, 2027, on March 25, 2026, leaving approximately $1.19B outstanding at 100% of principal plus accrued interest. No declines or flat performance metrics were reported.

• ·Presentation webcast available at https://event.webcasts.com/starthere.jsp?ei=1753406&tp_key=d357b0a0a7&tp_special=8; replay on www.centene.com Investors section
• ·Redemption price: 100% of principal plus accrued and unpaid interest to March 25, 2026

10-03-2026

Compass Minerals International, Inc. held its 2026 Annual Meeting of Stockholders on March 5, 2026, where all nine director nominees were elected with strong majorities, receiving between 32,889,655 and 35,476,006 votes in favor out of approximately 35.6M total votes cast (excluding 2,626,824 broker non-votes). Stockholders approved, on an advisory basis, the compensation of named executive officers with 29,868,622 votes for versus 5,669,317 against (excluding broker non-votes). The appointment of KPMG LLP as independent registered public accounting firm for fiscal 2026 was ratified with 38,136,077 votes for versus 73,743 against (no broker non-votes).

• ·Proxy Statement filed with SEC on January 23, 2026
• ·All director elections had consistent 2,626,824 broker non-votes
• ·Proposal 2 had 69,881 abstentions
• ·Proposal 3 had 24,824 abstentions and no broker non-votes

10-03-2026

TWFG, Inc. reported total revenues of $248.5M for 2025, up 22% YoY from $203.8M, driven by strong growth in commission income (+20.6%), contingent income (+50%), and TWFG MGA segment (+50.5%). Net income rose 44% to $41.2M, with adjusted net income up to $50.9M (margin 20.5% vs 16.2%), and adjusted diluted EPS of $0.90 (from $0.59); however, organic revenue growth slowed to 11.6% (revised methodology) from 15.2% prior year, reflecting moderated underlying expansion.

• ·Interest expense declined sharply to $287K from $2.2M YoY.
• ·Adjusted EBITDA increased to $66.8M (margin 26.9%) from $45.3M (22.3%).
• ·Diluted EPS $0.53 (from $0.19); legacy organic growth 11.4% vs 14.5% prior.

10-03-2026

Owlet, Inc., a smaller reporting company, filed a Form S-3 shelf registration statement on March 9, 2026, to register the resale of up to 9,643,647 shares of Class A Common Stock by certain registered holders. The shares consist of 2,647,762 issued in the Business Combination, 1,336,152 issued or issuable upon conversion of Series A Convertible Preferred Stock, 1,074,358 issuable upon conversion of Series B Convertible Preferred Stock, and 4,585,375 issued in the Warrant Exchange. This filing consolidates prior registration statements, with no proceeds to the company from the resales.

• ·Owlet, Inc. is a non-accelerated filer and smaller reporting company.
• ·Common Stock listed on NYSE under symbol 'OWLT'.
• ·Principal executive offices: 2940 West Maple Loop Drive, Suite 203, Lehi, Utah 84048.
• ·Filing consolidates prior registration statements: File Nos. 333-258506, 333-271459, 333-279375, 333-291697.

10-03-2026

Synchrony Financial furnished Monthly Charge-Off and Delinquency Statistics as of and for each of the thirteen months ended February 28, 2026, under Item 7.01 Regulation FD Disclosure via Exhibit 99.1. The company intends to continue providing these statistics monthly, with quarterly-end data released alongside financial results announcements. No specific metrics from the statistics are detailed in the filing body.

• ·Statistics cover thirteen months ended February 28, 2026
• ·Filing intends monthly releases going forward, aligned with quarterly results for period-end months
• ·Information in Item 7.01 and Exhibit 99.1 is furnished, not filed, under Regulation FD

10-03-2026

M&T Bank Corporation issued a DEFA14A notice for its 2026 Annual Meeting of Shareholders, to be held virtually on April 21, 2026, at 11:00 a.m. Eastern Time. Shareholders will vote on electing 12 directors for one-year terms, advisory approval of 2025 named executive officer compensation, amendment and restatement of the 2019 Equity Incentive Compensation Plan, and ratification of PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026. Proxy materials are available online at envisionreports.com/MTB, with requests for paper copies needed at least 10 days prior to the meeting.

• ·Virtual meeting URL: meetnow.global/MVLYTF9
• ·Proxy request methods: Internet at envisionreports.com/MTB, phone 1-866-641-4276, or email to investorvote@computershare.com
• ·Board recommends vote FOR all director nominees, Proposal 2, Proposal 3, and Proposal 4

10-03-2026

Walker & Dunlop hosted Investor Day 2026, highlighting its 'Journey to ‘30' strategy targeting $80B+ annual origination volume, $35B+ property sales volume, $2B+ total revenues, and $400-500M adjusted EBITDA. Historical scale-up included employee growth to 1,466 and 46 offices by 2025, with market leadership as #1 Fannie Mae DUS lender, #3 Freddie Mac Optigo, and #4 multifamily broker; however, adjusted EBITDA declined 4% YoY to $316M in 2025 from $329M in 2024 amid rate-driven transaction volume drops (e.g., per banker/broker fell to $141M in 2023 before recovering to $248M). MSR revenue declined due to duration shifts and fee compression despite GSE origination activity.

• ·Debt origination volume dropped to $429B market-wide in 2023 before rising to $634B in 2025 amid rising 10yr UST rates.
• ·#1 Fannie Mae DUS® lender, #3 Freddie Mac Optigo® lender, #2 combined GSE lender, and #4 multifamily broker in 2025.
• ·Institutional CRE AUM for Carlyle, Blackstone, Ares, KKR grew at 28% CAGR, outpacing market 10% CAGR.

10-03-2026

BioNTech SE's FY2025 revenues increased 4% YoY to €2.87B from €2.75B, driven by €613M in new out-licensing revenues, however COVID-19 vaccine revenues declined 18% to €2.0B and other revenues fell 18% to €262M. The company reported a widened net loss of €1.14B versus €665M loss in 2024, with operating loss deepening to €1.40B due to sharply higher other operating expenses of €1.09B, though adjusted net loss narrowed to €117M from a €122M profit. Operating cash flow improved to €456M from €208M amid ongoing investments.

• ·Research and development expenses decreased to €2.10B in FY2025 from €2.25B in FY2024.
• ·Income taxes expense swung to €85.3M in FY2025 from income of €12.4M in FY2024.
• ·Net cash used in investing activities increased to €2.47B in FY2025 from €2.08B in FY2024.
• ·Basic loss per share worsened to €4.70 in FY2025 from €2.77 in FY2024.
• ·Filing date: March 10, 2026 for year ended December 31, 2025.

10-03-2026

Duke Energy Corporation announced the pricing of an upsized private placement of $1.3B principal amount of 3.000% Convertible Senior Notes due 2029 on March 10, 2026, increasing the offering size from the previously announced $1B. The press release detailing the transaction is filed as Exhibit 99.1. No declines or underperformance were reported in this financing update.

• ·Offering structured as a private placement.
• ·Securities registered include Common Stock (DUK), 5.625% Junior Subordinated Debentures due September 15, 2078 (DUKB), Depositary Shares 5.75% Series A (DUK PR A), 3.10% Senior Notes due 2028 (DUK 28A), 3.85% Senior Notes due 2034 (DUK 34), and 3.75% Senior Notes due 2031 (DUK 31A).

10-03-2026

Custom Truck One Source, Inc. (CTOS) reported total revenue of $1.94B for FY 2025, up 7.9% YoY from $1.80B, driven by strong rental revenue growth of 14.3% to $506.2M and equipment sales up 6.7% to $1.30B, though parts sales and services declined 2.2% to $133.3M. Gross profit rose 5.5% to $411.9M with fleet utilization improving 6.9% to 79.4%, but operating income dipped 1.1% to $124.9M and net loss widened 8.4% to $31.1M amid higher expenses. Adjusted EBITDA increased 12.9% to $383.6M, while sales order backlog fell 9.1% to $335.3M and net leverage improved to 4.31x from 4.55x.

• ·Ending OEC grew 8.0% YoY to $1.64B; Average OEC on rent up 14.1% to $1.26B.
• ·Depreciation of rental equipment increased 17.5% to $215.6M.
• ·Gain on sale leaseback transaction was $0 in 2025 vs $23.5M in 2024.

10-03-2026

Q32 Bio reported Q4 2025 net income of $57.7M versus a $14.2M loss in Q4 2024, and full-year net income of $29.8M versus a $47.7M loss in 2024, primarily driven by $53.7M collaboration revenue from Amgen amendment and $11.7M gain on ADX-097 asset sale to Akebia; however, cash and equivalents declined to $48.3M from $78.0M YoY, R&D expenses dropped 69% QoQ to $3.3M reflecting program wind-downs, while G&A rose 14% QoQ to $4.5M. The company completed a $10.5M RDO in Feb 2026 and secured near-term milestones from the asset sale, extending runway to Q4 2027. Clinical milestones include enrollment completion in SIGNAL-AA Part B (33 patients, expanded from initial size) with 36-week topline data expected mid-2026, showing early pharmacokinetic improvements.

• ·Terminated all remaining obligations to Amgen via one-time equity grant.
• ·ADX-097 sale includes tiered royalties from low single-digit to mid-teen percentages on future sales.
• ·SIGNAL-AA Part B dosing: 200mg weekly loading for 4 doses, then 200mg every other week for 32 weeks.
• ·Preliminary PK data shows steady state achieved 9 weeks earlier in Part B vs Part A due to loading regimen.

10-03-2026

UNFI's Q2 FY26 net sales declined 2.6% YoY to $7.9B, driven by a 12.1% drop in conventional sales and 8.2% in retail due to network optimization actions, though natural sales grew 6.7%. Profitability strengthened significantly with Adjusted EBITDA up 23.4% to $179M, Adjusted EPS rising to $0.62 from $0.22, and free cash flow increasing 25.9% to $243M. The company updated FY26 outlook, lowering net sales to $31.0-$31.4B but raising Adjusted EBITDA to $680-$710M, net income to $50-$75M, and free cash flow to ~$330M.

• ·Net leverage ratio declined to 2.7x as of Jan 31, 2026, with expectation of ~2.3x by FY26 end.
• ·Operating expenses declined nearly 6% to $972M (12.2% of sales vs. 12.6% prior year).
• ·Gross profit rate improved to 13.2% from 13.1%.
• ·Interest expense decreased to $32M from $38M.
• ·Target addressable market of $90B.
• ·FY26 outlook for capital expenditures ~$250M.

10-03-2026

Apyx Medical Corporation reported record Q4 2025 total revenue of $19.2 million, up 34.7% YoY from $14.2 million, driven by 38.1% growth in Surgical Aesthetics to $16.7 million and 15.6% increase in OEM to $2.5 million. Full year 2025 revenue grew 9.9% to $52.8 million, with Surgical Aesthetics up 17.4% to $45.3 million, however OEM declined 20.9% to $7.5 million and international revenue was essentially flat at -0.3%. The company issued FY2026 guidance of $57.5-58.5 million total revenue, anticipating further OEM decline to $4.5 million.

• ·Q4 2025 net loss attributable to stockholders: $1.3M ($0.03 per share) vs. $4.6M ($0.12 per share) in Q4 2024
• ·FY 2025 net loss attributable to stockholders: $11.2M ($0.27 per share) vs. $23.5M ($0.66 per share) in FY 2024
• ·Q4 2025 Adjusted EBITDA: $0.7M vs. -$2.2M in Q4 2024
• ·FY 2025 Adjusted EBITDA loss: $3.8M vs. $14.3M in FY 2024
• ·Q4 2025 gross margin: 62.6% (flat vs. 63.0% in Q4 2024)
• ·FY 2025 gross margin: 62.5% (up from 61.0% in FY 2024)
• ·Q4 operating expenses flat at $12.0M
• ·AYON launched September 2025; potential 510(k) clearance mid-2026
• ·Conference call: March 10, 2026 at 8:00 a.m. ET

10-03-2026

Inspired Entertainment reported Q4 2025 revenue of $77.2 million, down 7% YoY due to declines in Gaming (-6%), Virtual Sports (-7%), and Leisure (-39%), partially offset by record Interactive revenue of $17.8 million, up 53% YoY. Adjusted EBITDA increased 5% to a record $32.3 million (42% margin), driven by Interactive's 60% YoY growth, though the company posted a net loss of $7.2 million versus prior year's profit. Full year 2025 revenue grew 2% to $304.1 million with Adjusted EBITDA up 11% to $111.4 million (37% margin), and management guided FY2026 Adjusted EBITDA to $112-118 million with Q1 2026 at least +20% YoY.

• ·Sold UK Holiday Parks and leisure assets for £18.6 million on November 7, 2025.
• ·U.S. iGaming GGR market share increased 50 basis points QoQ in Q4 2025.
• ·Digital businesses represent 52% of Adjusted EBITDA post-divestiture.
• ·Upcoming reporting change: Merge Gaming and Leisure into 'Retail Solutions' segment starting Q1 2026.

10-03-2026

Howmet Aerospace Inc. posted its Technology and Markets Day presentation to its website on March 10, 2026, disclosed via Form 8-K under Item 7.01 Regulation FD Disclosure. The presentation is attached as Exhibit 99.1. The information is not deemed 'filed' for purposes of Section 18 of the Exchange Act or subject to liability.

10-03-2026

Kohl’s reported Q4 FY2025 net sales of $5.0B, down 3.9% YoY with comparable sales down 2.8%, while full-year net sales fell 4.0% to $14.8B with comparable sales down 3.1%; however, operating income rose to $212M in Q4 (from $126M) and $624M full-year (from $433M), driven by gross margin expansion and SG&A reductions. Adjusted diluted EPS improved to $1.07 in Q4 and $1.62 full-year, with strong cash flow from operations at $750M in Q4 and $1.4B full-year. The company introduced FY2026 guidance for net sales down 2% to flat and share repurchases via dividend of $0.125/share.

• ·Borrowings under revolving credit facility reduced to $0 from $290M YoY.
• ·FY2026 guidance: Adjusted operating margin 2.8% to 3.4%; Adjusted diluted EPS $1.00 to $1.60; Capex $350M to $400M.
• ·Quarterly dividend $0.125 per share, payable April 1, 2026 to shareholders of record March 18, 2026.
• ·Cash and equivalents increased to $674M from $134M.

10-03-2026

Willis Lease Finance Corporation (WLFC) reported record 2025 full-year results with total revenue of $730.2M, up 28.3% YoY from $569.2M, driven by lease rent revenue of $291.6M (+22.4% YoY) and spare parts/equipment sales of $95.5M (+252.3% YoY), alongside pre-tax income of $160.6M (+5.2% YoY). However, growth moderated in maintenance reserve revenue to +8.4% YoY at $232.0M, and Q4 showed declines including maintenance reserve revenue down 12.3% YoY, gain on sale of leased equipment down 50.7% YoY, and income from operations down 52.0% YoY. Adjusted EBITDA increased 16.6% to $459.1M, while average portfolio utilization rose to 84.9% from 82.9%.

• ·Book value of lease assets $3,614.5M as of Dec 31, 2025.
• ·Debt obligations increased to $2,700.3M from $2,264.6M YoY.
• ·Write-down of equipment $32.9M in 2025, up 193.4% YoY.
• ·Interest expense $132.1M in 2025, up 26.1% YoY.
• ·Gain on sale of business $43.0M in 2025.
• ·Conference call scheduled for March 10, 2026 at 10:00 a.m. EST.

10-03-2026

Stagwell Inc. reported FY25 revenue growth of 2% YoY to $2.91B and net revenue growth of 6% to $2.43B, with stronger ex-Advocacy net revenue up 9% to $2.28B driven by Digital Transformation (+13%) and Marketing Cloud (+230%); however, overall Adjusted EBITDA grew modestly 1% to $422M, reflecting tempered performance including flatish Advocacy contributions. Free cash flow more than doubled to $187M, net new business reached $476M LTM, and the company announced a $350M increase to its stock repurchase program ($400M available). 2026 guidance projects net revenue growth of 8-12% and Adjusted EBITDA of $475-525M.

• ·Q4 Adjusted EBITDA margin of 20% on net revenue; FY25 Adjusted EBITDA margin of 17% on net revenue.
• ·Repurchase Program expires March 4, 2029; previously approved program extended.
• ·2026 guidance: Adjusted EPS of $0.98 - $1.12; Free Cash Flow Conversion of 50% to 60%.
• ·Video webcast on March 10, 2026 at 8:30 a.m. (ET).

10-03-2026

Esperion Therapeutics reported strong FY25 total revenue growth of 21% YoY to $403.1M, driven by 38% YoY U.S. net product revenue increase to $159.6M and Q4 total revenue surge of 144% YoY to $168.4M, fueled by a $90M Otsuka milestone and robust U.S. prescriptions up 34% YoY. However, the company posted a FY25 net loss of $22.7M (improved from $51.7M prior year), with R&D expenses up 4% YoY to $47.9M, SG&A up 2% to $165.8M, and Q4 royalty revenue down 11% QoQ despite 51% YoY growth. The company announced an agreement to acquire Corstasis Therapeutics to add Enbumyst™, targeting a >$4B U.S. market, aligning with Vision 2040.

• ·2026 operating expenses expected $225M-$255M including ~$15M non-cash stock compensation.
• ·Cash increased to $167.9M from $144.8M YoY.
• ·Patent settlements restrict generic entry until April 2040; remaining patents expire March 2036 or June 2040.
• ·NEXLETOL/NEXLIZET coverage exceeds 90% commercial lives and Medicare beneficiaries.
• ·Otsuka Japan launch in late 2025; NEXLIZET Canada approval expected 2026; Israel approval H1 2026; Australia/NZ Q4 2026.
• ·IND-enabling studies for ESP-2001 underway, IND submission 2026 for PSC.

10-03-2026

Opus Genetics reported FY 2025 financial results with revenue increasing 29% YoY to $14.2M from $11.0M, driven by Viatris collaboration, and a narrowed net loss of $49.6M ($0.80/share) versus $57.5M ($2.15/share) in 2024, primarily due to no repeat of a $28M IPR&D charge. However, R&D expenses rose 15% to $30.8M and G&A expenses increased 21% to $22.0M amid pipeline advancement. Cash stood at $45.1M as of Dec 31, 2025, bolstered by $25M raised post-year end for a $70.1M runway into H1 2028, alongside positive early BEST1 data and upcoming catalysts like PDUFA in Oct 2026.

• ·FDA PDUFA date of October 17, 2026 for Phentolamine Ophthalmic Solution 0.75% sNDA in presbyopia.
• ·Three-month results from full Cohort 1 of OPGx-BEST1 expected mid-2026.
• ·LYNX-3 Phase 3 topline results expected H1 2026.
• ·Phase 1/2 six-month pediatric cohort data for OPGx-LCA5 at ARVO May 2026.
• ·Total assets $50.2M as of Dec 31, 2025 (up from $36.9M in 2024).

10-03-2026

Passage Bio, Inc. terminated its 15-year lease for approximately 62,000 square feet of laboratory space with Hopewell Campus Owner LLC, effective March 4, 2026, following a January 2025 restructuring that ceased operations at the site. The termination required a $4.8M fee plus accrued rent through February 14, 2026, representing a near-term cash outflow. However, the company expects its cash and cash equivalents to fund operations through Q1 2027.

• ·Original Hopewell Lease dated December 15, 2020, with 15-year term from March 2021 commencement.
• ·Lease termination agreement executed March 4, 2026; 8-K filed March 10, 2026.